Stocks and Investing
Stocks and Investing
Wed, April 14, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, April 13, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Liana Moussatos Maintained (BPMC) at Buy with Increased Target to $136 on, Apr 13th, 2021
Liana Moussatos of Wedbush, Maintained "Blueprint Medicines Corporation" (BPMC) at Buy with Increased Target from $119 to $136 on, Apr 13th, 2021.
Liana has made no other calls on BPMC in the last 4 months.
There are 4 other peers that have a rating on BPMC. Out of the 4 peers that are also analyzing BPMC, 3 agree with Liana's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brad Canino of "Credit Suisse" Initiated at Hold and Held Target at $100 on, Wednesday, March 31st, 2021
- David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $105 on, Thursday, February 18th, 2021
- Peter Lawson of "Barclays" Maintained at Hold with Increased Target to $95 on, Thursday, February 18th, 2021
This is the rating of the analyst that currently disagrees with Liana
- Andrew Berens of "SVB Leerink" Maintained at Buy with Increased Target to $127 on, Tuesday, January 12th, 2021
Contributing Sources